Early studies and reviews suggest GLP-1 medications may reduce binge episodes in some individuals by reducing cravings and reward-driven eating
PMID: 7043459 PMCID: PMC345726
SUT, supratrigmental nucleus
The SURPASS-5 study assessed the efficacy and safety of an injectable combination therapy combining tirzepatide with insulin glargine (75)
Key points: GLP-1s (glucagon-like peptide-1 receptor agonists) support type 2 diabetes by reducing appetite and supporting weight loss alongside their effects on the pancreas GLP-1-assisted programmes lead to a clinically significant weight loss of 10% or more, which can significantly reduce complications associated with obesity Combining semaglutide with lifestyle interventions leads to significantly more weight loss than lifestyle interventions alone, with 87% of participants losing more than 10% of their body weight Semaglutide is more effective at supporting weight loss than liraglutide Tirzepatide is more effective than semaglutide at reducing weight, with all three doses of tirzepatide leading to more significant weight loss than 1mg of semaglutide The higher doses of tirzepatide (10mg and 15mg) might reduce weight by 5.15kg more than 2mg of semaglutide, while there appears to be no difference between 5mg of tirzepatide and 2mg of semaglutide 3) Side effects and safety All medications have possible side effects, particularly if you live with other health conditions
While findings so far are promising, understanding the nuances of the evidence is essential when talking with patients
